The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe.


Journal

BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547

Informations de publication

Date de publication:
21 Jan 2020
Historique:
received: 27 06 2019
accepted: 06 01 2020
entrez: 23 1 2020
pubmed: 23 1 2020
medline: 29 10 2020
Statut: epublish

Résumé

Patients with ulcerative colitis (UC) experience periods of recurring and episodic clinical signs and symptoms. This study sought to establish the association between disease activity and health-related quality of life (HRQoL) and other patient-reported outcomes. United States (US) and European Union 5 ([EU5]; i.e., France, Germany, Italy, Spain, and the United Kingdom) data from the 2015 and 2017 Adelphi Inflammatory Bowel Disease-Specific Programme (IBD-DSP) were used. The IBD-DSP is a database of retrospective patient chart information integrated with patient survey data (EuroQoL-5 Dimensions [EQ-5D], Short Quality of Life in Inflammatory Bowel Disease Questionnaire [SIBDQ], and Work Productivity and Activity Impairment-Ulcerative Colitis [WPAI-UC] questionnaire). Using available chart information, physicians classified their moderate-to-severe patients into one of the following categories: remission with a Mayo endoscopic score = 0 ("deep remission"), remission without a Mayo endoscopic score = 0 ("remission"), or active disease. Differences among disease activity categories with respect to patient-reported outcomes were analyzed using generalized linear models, controlling for confounding variables. N = 289 and N = 1037 patient charts with linked surveys were included from the US and EU5, respectively. The disease activity distribution was as follows: active disease = 40.1% (US) and 33.6% (EU5); remission = 48.0 and 53.0%; deep remission = 11.9 and 13.3%. Patients with active disease reported significantly lower levels of EQ-5D health state utilities (adjusted mean [AdjM] = 0.87 [US] and 0.78 [EU5]) compared with remission (AdjM = 0.92 and 0.91) and deep remission (AdjM = 0.93 and 0.91) (all P < 0.05 compared with active disease within each region). Similar findings were observed with the scores from the SIBDQ and the WPAI-UC. No significant differences were observed between remission categories. Among patients with moderate-to-severe UC in the US and EU5, active disease was associated with significant impairments in HRQoL, work and leisure activities. These results reinforce the importance, to both the patient and society, of achieving some level of remission to restore generic and disease-related HRQoL and one's ability to work productively.

Sections du résumé

BACKGROUND BACKGROUND
Patients with ulcerative colitis (UC) experience periods of recurring and episodic clinical signs and symptoms. This study sought to establish the association between disease activity and health-related quality of life (HRQoL) and other patient-reported outcomes.
METHODS METHODS
United States (US) and European Union 5 ([EU5]; i.e., France, Germany, Italy, Spain, and the United Kingdom) data from the 2015 and 2017 Adelphi Inflammatory Bowel Disease-Specific Programme (IBD-DSP) were used. The IBD-DSP is a database of retrospective patient chart information integrated with patient survey data (EuroQoL-5 Dimensions [EQ-5D], Short Quality of Life in Inflammatory Bowel Disease Questionnaire [SIBDQ], and Work Productivity and Activity Impairment-Ulcerative Colitis [WPAI-UC] questionnaire). Using available chart information, physicians classified their moderate-to-severe patients into one of the following categories: remission with a Mayo endoscopic score = 0 ("deep remission"), remission without a Mayo endoscopic score = 0 ("remission"), or active disease. Differences among disease activity categories with respect to patient-reported outcomes were analyzed using generalized linear models, controlling for confounding variables.
RESULTS RESULTS
N = 289 and N = 1037 patient charts with linked surveys were included from the US and EU5, respectively. The disease activity distribution was as follows: active disease = 40.1% (US) and 33.6% (EU5); remission = 48.0 and 53.0%; deep remission = 11.9 and 13.3%. Patients with active disease reported significantly lower levels of EQ-5D health state utilities (adjusted mean [AdjM] = 0.87 [US] and 0.78 [EU5]) compared with remission (AdjM = 0.92 and 0.91) and deep remission (AdjM = 0.93 and 0.91) (all P < 0.05 compared with active disease within each region). Similar findings were observed with the scores from the SIBDQ and the WPAI-UC. No significant differences were observed between remission categories.
CONCLUSIONS CONCLUSIONS
Among patients with moderate-to-severe UC in the US and EU5, active disease was associated with significant impairments in HRQoL, work and leisure activities. These results reinforce the importance, to both the patient and society, of achieving some level of remission to restore generic and disease-related HRQoL and one's ability to work productively.

Identifiants

pubmed: 31964359
doi: 10.1186/s12876-020-1164-0
pii: 10.1186/s12876-020-1164-0
pmc: PMC6975026
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

18

Références

Clin Gastroenterol Hepatol. 2017 Jun;15(6):857-863
pubmed: 27856364
Frontline Gastroenterol. 2014 Jul;5(3):183-189
pubmed: 28839768
Am J Gastroenterol. 2001 Oct;96(10):2921-8
pubmed: 11693327
Gastroenterology. 2012 Nov;143(5):1179-1187.e3
pubmed: 22885331
Am J Gastroenterol. 2010 Mar;105(3):501-23; quiz 524
pubmed: 20068560
Prz Gastroenterol. 2018;13(1):61-68
pubmed: 29657613
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
J Gastroenterol Hepatol. 2017 Nov;32(11):1818-1824
pubmed: 28370253
Dig Liver Dis. 2016 Jun;48(6):592-600
pubmed: 26935454
J Crohns Colitis. 2015 Aug;9(8):625-32
pubmed: 25956537
Gastroenterology. 2012 Jan;142(1):46-54.e42; quiz e30
pubmed: 22001864
J Crohns Colitis. 2013 May;7(4):322-37
pubmed: 23395397
Lancet. 2017 Apr 29;389(10080):1756-1770
pubmed: 27914657
Curr Med Res Opin. 2008 Nov;24(11):3063-72
pubmed: 18826746
J Inflamm Res. 2014 Jun 23;7:113-20
pubmed: 25075198
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
J Med Econ. 2015 Jun;18(6):447-56
pubmed: 25728698
J Crohns Colitis. 2018 Apr 27;12(5):600-609
pubmed: 29718244

Auteurs

Alessandro Armuzzi (A)

Fondazione Policlinico A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy.

Miriam Tarallo (M)

Pfizer Inc, Rome, Italy.

James Lucas (J)

Adelphi Real World, Macclesfield, UK.

Daniel Bluff (D)

Adelphi Real World, Macclesfield, UK.

Benjamin Hoskin (B)

Adelphi Real World, Macclesfield, UK.

Danielle Bargo (D)

Pfizer Inc, New York, NY, USA.

Joseph C Cappelleri (JC)

Pfizer Inc, Groton, CT, USA.

Leonardo Salese (L)

Pfizer Inc, Collegeville, PA, USA.

Marco daCosta DiBonaventura (M)

Pfizer Inc, New York, NY, USA. Marco.DiBonaventura@pfizer.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH